X-linked severe combined immunodeficiency (X-SCID) with high blood levels of immunoglobulins and Aspergillus pneumonia successfully treated with micafangin followed by unrelated cord blood stem cell transplantation
- 134 Downloads
In this report, we describe a patient with X-linked severe combined immunodeficiency (X-SCID) who had high serum IgG, IgA, and IgM levels. The boy did well until 6 months of age, when he developed interstitial pneumonia caused by Aspergillus species, with a white cell count of 12,840/μL and only 10% lymphocytes; IgG, 991 mg/dL; IgA, 65 mg/dL; IgM, 472 mg/dL. Cell markers showed only 6.3% CD3, 2.1% CD4, 0.7% CD8, but 92% CD19 and 0.1% CD16+CD56+ (NK cells). A mutation was detected within exon 2 (C196 A→C), leading to the substitution of proline for glutamine, which has not been reported previously. The boy was successfully treated with the new antifungal drug, micafangin (MCFG), at 5 mg/kg/day for 89 days. After resolution of the pneumonia, the patient underwent successful hematopoietic stem cell transplantation with completely matched unrelated female cord blood. The CD34 stem cell dose was 3.4×104 cells/kg. In conclusion, MCFG can be a first line agent for Aspergillus pneumonia in immunocompromised hosts.
KeywordsX-SCID Micafangin Paraprotein Cord blood transplantation
Severe combined immunodeficiency
X-linked severe combined immunodeficiency
We thank Dr. Satoshi Kume of the Institute of Development, Aging and Cancer, Tohoku University, Japan, for genetic analysis of the patient samples.
- 4.Fisher A, Notarangelo LD (2004) Combined immunodeficiencies. In: Stiehm ER, Ochs HD, Winkelstein JA (eds) Immunological disorders in infants and children, 5th edn. Elsevier Saunders, Philadelphia, Pennsylvania, pp 447–479Google Scholar
- 7.Herbrecht R, Denning DW, Patterson TF, Benett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, Pauw B (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347(6):408–415PubMedCrossRefGoogle Scholar
- 8.Stephan JL, Viekoba V, Le Deist F, Blanche S, Donadieu J, De Saint-Basile G, Durandy A, Gricelli C, Fisher A (1993) Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr 123(4):565–572Google Scholar
- 9.Walsh TJ, Pappas P, Winston DJ, Lazarus MH, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Lee J (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346(4):225–234PubMedCrossRefGoogle Scholar